Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VAX 31

Next Previous
Drug Profile

VAX 31

Alternative Names: 31-valent PCV; 31-Valent Pneumococcal Conjugate Vaccine - Vaxcyte; Pneumonococcal conjugate vaccine - Vaxcyte; VAX-31; VAX-XP

Latest Information Update: 03 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaxcyte
  • Class Conjugate vaccines; Pneumococcal vaccines; Protein vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pneumococcal infections
  • No development reported Otitis media

Most Recent Events

  • 23 Mar 2026 Vaxcyte completes enrolment in its phase-III OPUS-2 trial for Pneumococcal infections (Prevention, In adults, In the elderly, Combination therapy) in USA (IM) (NCT07365826)
  • 23 Mar 2026 Vaxcyte completes enrolment in its phase III OPUS-1 trial for Pneumococcal infections (Prevention, In adults, In the elderly) in USA (IM, injection) (NCT07284654)
  • 18 Mar 2026 Updated immunogenicity and adverse events data from a phase I/II trial in Pneumococcal infections released by Vaxcyte

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top